Thymidylate synthase : A predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment
(2018) In Future Oncology 14(4). p.343-351- Abstract
Aim: To investigate the role of thymidylate synthase (TS) as a predictive biomarker in patients with resected colorectal liver metastases (CRLM). Materials & methods: PubMed, EMBASE and Cochrane Library were queried up to June 2017. Meta-analysis was performed using random-effects model. Risk of bias was assessed using funnel plots. Results: Six eligible studies were included, comprising a total of 542 patients. Meta-analysis demonstrated a trend to reduced overall survival in patients with resected CRLM with TS overexpression, with a hazard ratio of 1.13 (95% CI: 0.99-1.29; p = 0.08). In three studies where patients received systemic fluorouracil, the pooled hazard ratio was 2.25 (95% CI: 1.37-3.71; p = 0.001). Conclusion: TS... (More)
Aim: To investigate the role of thymidylate synthase (TS) as a predictive biomarker in patients with resected colorectal liver metastases (CRLM). Materials & methods: PubMed, EMBASE and Cochrane Library were queried up to June 2017. Meta-analysis was performed using random-effects model. Risk of bias was assessed using funnel plots. Results: Six eligible studies were included, comprising a total of 542 patients. Meta-analysis demonstrated a trend to reduced overall survival in patients with resected CRLM with TS overexpression, with a hazard ratio of 1.13 (95% CI: 0.99-1.29; p = 0.08). In three studies where patients received systemic fluorouracil, the pooled hazard ratio was 2.25 (95% CI: 1.37-3.71; p = 0.001). Conclusion: TS appears to be a clinically relevant predictive biomarker in patients with resected CRLM receiving systemic 5-FU.
(Less)
- author
- Torén, William LU ; Ansari, Daniel LU ; Andersson, Bodil LU ; Spelt, Lidewij LU and Andersson, Roland LU
- organization
- publishing date
- 2018-02-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- biomarker, colorectal liver metastases, predictive, prognosis, thymidylate synthase
- in
- Future Oncology
- volume
- 14
- issue
- 4
- pages
- 9 pages
- publisher
- Future Medicine Ltd.
- external identifiers
-
- pmid:29318904
- scopus:85041331404
- ISSN
- 1479-6694
- DOI
- 10.2217/fon-2017-0431
- language
- English
- LU publication?
- yes
- id
- 6922c5c4-90b7-44d6-9923-0b88bed8a07d
- date added to LUP
- 2018-03-06 12:41:25
- date last changed
- 2024-06-24 10:56:48
@article{6922c5c4-90b7-44d6-9923-0b88bed8a07d, abstract = {{<p>Aim: To investigate the role of thymidylate synthase (TS) as a predictive biomarker in patients with resected colorectal liver metastases (CRLM). Materials & methods: PubMed, EMBASE and Cochrane Library were queried up to June 2017. Meta-analysis was performed using random-effects model. Risk of bias was assessed using funnel plots. Results: Six eligible studies were included, comprising a total of 542 patients. Meta-analysis demonstrated a trend to reduced overall survival in patients with resected CRLM with TS overexpression, with a hazard ratio of 1.13 (95% CI: 0.99-1.29; p = 0.08). In three studies where patients received systemic fluorouracil, the pooled hazard ratio was 2.25 (95% CI: 1.37-3.71; p = 0.001). Conclusion: TS appears to be a clinically relevant predictive biomarker in patients with resected CRLM receiving systemic 5-FU.</p>}}, author = {{Torén, William and Ansari, Daniel and Andersson, Bodil and Spelt, Lidewij and Andersson, Roland}}, issn = {{1479-6694}}, keywords = {{biomarker; colorectal liver metastases; predictive; prognosis; thymidylate synthase}}, language = {{eng}}, month = {{02}}, number = {{4}}, pages = {{343--351}}, publisher = {{Future Medicine Ltd.}}, series = {{Future Oncology}}, title = {{Thymidylate synthase : A predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment}}, url = {{http://dx.doi.org/10.2217/fon-2017-0431}}, doi = {{10.2217/fon-2017-0431}}, volume = {{14}}, year = {{2018}}, }